PeptideDB

C3a 70-77 63555-63-5

C3a 70-77 63555-63-5

CAS No.: 63555-63-5

C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a and displays C3a specificity and 1 to 2% bioacti
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a and displays C3a specificity and 1 to 2% bioactivity.

Physicochemical Properties


Molecular Formula C35H61N13O10
Molecular Weight 823.94000
Exact Mass 823.466
CAS # 63555-63-5
Related CAS # C3a (70-77) (TFA)
PubChem CID 9918922
Appearance Typically exists as solid at room temperature
Density 1.44 g/cm3
Index of Refraction 1.638
LogP 0.404
Hydrogen Bond Donor Count 13
Hydrogen Bond Acceptor Count 13
Rotatable Bond Count 26
Heavy Atom Count 58
Complexity 1440
Defined Atom Stereocenter Count 7
SMILES

CC(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](N)C)=O)CO)=O)CC1=CN=CN1)=O)C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)C)=O)CC(C)C)=O)=O)C

InChi Key LYTNSBOBASKUDN-GUQPKPMOSA-N
InChi Code

InChI=1S/C35H61N13O10/c1-17(2)10-23(46-32(55)25(12-21-13-39-16-42-21)47-33(56)26(15-49)48-28(51)19(5)36)30(53)41-14-27(50)44-24(11-18(3)4)31(54)43-20(6)29(52)45-22(34(57)58)8-7-9-40-35(37)38/h13,16-20,22-26,49H,7-12,14-15,36H2,1-6H3,(H,39,42)(H,41,53)(H,43,54)(H,44,50)(H,45,52)(H,46,55)(H,47,56)(H,48,51)(H,57,58)(H4,37,38,40)/t19-,20-,22-,23-,24-,25-,26-/m0/s1
Chemical Name

(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro Human mononuclear leukocytes in culture are directly impacted by C3a(70–77), which inhibits the generation of LIF generated by mitogens and antigens in a concentration-dependent manner. At doses of 10-7 M or greater, C3a(70-77) significantly inhibited the synthesis of LIF regardless of the stimulus, with suppression surpassing 75% at concentrations of 10-6 M [1]. C3a (70–77) increases vascular permeability in human skin, stimulates tissue contraction in the ileum of guinea pigs, and causes histamine release and mast cell degranulation. Ileal smooth muscle is desensitized to C3a (70–77) but not to human C5a, a similar anaphylatoxin. On the other hand, ileal smooth muscle preconditioned with native C3a was unresponsive to C3a-(70-77). According to this cross-desensitization, C3a (70–77) only interacts with the C3a binding sites in cells [2].
References

[1]. Modulation of human lymphocyte function by C3a and C3a(70-77). J Exp Med. 1982 Sep 1;156(3):756-65.

[2]. The active site of C3a anaphylatoxin. J Biol Chem. 1980 Nov 25;255(22):10758-63.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.2137 mL 6.0684 mL 12.1368 mL
5 mM 0.2427 mL 1.2137 mL 2.4274 mL
10 mM 0.1214 mL 0.6068 mL 1.2137 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.